en · de · es · fr · pt
sr9009-notes.peptides3626.com › Blog › Mechanism And Preclinical Findings — Questions and Answers

Mechanism And Preclinical Findings — Questions and Answers

By Editorial Desk · published 2025-12-21 · last reviewed 2026-02-12 · Blog

This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-02-12. Anything still debated is marked as such rather than presented as settled.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Detection, Regulation, and Misconceptions

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Related pages on this site

Background from the literature

=== Alternatives to approved sources === Gray market sellers offer unauthorized products they claim are GLP-1 agonists. Some buyers turn to unauthorized retailers if they cannot afford the name-brand drug. Buyers face risks due to counterfeit or substandard drugs. In the United States, compounding pharmacies may sell custom-made versions of a drug if there is a declared shortage and they obtain the active pharmaceutical ingredient from an FDA-approved facility. The FDA declared shortages of injectable versions of semaglutide, tirzepatide, dulaglutide, liraglutide, and exenatide in 2022. The tirzepatide shortage ended in 2024. Al Carter, executive director of the National Association of Boards of Pharmacy, a trade organization for pharmacy regulators, estimated that 95% of online compounding pharmacies were operating illegally in 2024. As of January 2026, there were up to 1.5 million users of compounded GLP-1 receptor agonist drugs in the U.S., according to Novo Nordisk CEO Mike Doustdar. He decried the practice of selling what he called "unsafe, knock-off products" while conceding that compounding pharmacies capture price-sensitive consumers in a way that his company, with its more expensive branded offerings, cannot.

Hydrocodone/paracetamol (also known as hydrocodone/acetaminophen) is the combination of the pain medications hydrocodone (an opioid) and paracetamol (acetaminophen). It is used to treat moderate to severe pain. It is taken by mouth. Recreational use is common in the United States. Common side effects include dizziness, sleepiness, constipation, and vomiting. Serious side effects include addiction, decreased rate of breathing, low blood pressure, severe allergic reactions, and liver failure. Use during pregnancy may harm the fetus. Use with alcohol is not recommended. Hydrocodone works by binding to the mu-opioid receptor. How paracetamol works is unclear but may involve blocking the creation of prostaglandins. Hydrocodone/paracetamol was approved for medical use in the United States in 1982. In the United States, it is a schedule II controlled substance. In 2023, it was the 25th most commonly prescribed medication in the United States, with more than 21 million prescriptions. It is not available in the United Kingdom, though the combination codeine/paracetamol (co-codamol) is. It is sold under the brand names Vicodin and Norco among others.

The music of Brazil was formed mainly from the fusion of European, Native Indigenous, and African elements. Until the nineteenth century, Portugal was the gateway to most of the influences that built Brazilian music, although many of these elements were not of Portuguese origin, but generally European. The first was José Maurício Nunes Garcia, author of sacred pieces with an influence of Viennese classicism. The major contribution of the African element was the rhythmic diversity and some dances and instruments. Popular music since the late eighteenth century, samba was considered the most typical and on the UNESCO cultural heritage list. Samba-reggae, Axé, Maracatu, Frevo and Afoxê are four music traditions that have been popularized by their appearance in the annual Brazilian Carnivals. Capoeira is usually played with its own music referred to as capoeira music, which is usually considered to be a call-and-response type of folk music. Forró is a type of folk music prominent during the Festa Junina in northeastern Brazil. Jack A. Draper III, a professor of Portuguese at the University of Missouri, argues that Forró was used as a way to subdue feelings of nostalgia for a rural lifestyle. Choro is a popular musical instrumental style. Its origins are in 19th-century Rio de Janeiro. The style often has a fast and happy rhythm, characterized by subtle modulations and full of syncopation and counterpoint. lambada and Carimbó achieved success in Latin music, originating from Pará.

Sources: en.wikipedia.org

Further detail

=== Influence on other special forces === Following the post-war reconstitution of the Special Air Service, other countries in the Commonwealth recognised their need for similar units. The Canadian Special Air Service Company was formed in 1947, being disbanded in 1949. The New Zealand Special Air Service squadron was formed in June 1955 to serve with the British SAS in Malaya, which became a full regiment in 2011. Australia formed the 1st SAS Company in July 1957, which became a full regiment of the Special Air Service Regiment (SASR) in 1964. On its return from Malaya, the C (Rhodesian) Squadron formed the basis for creation of the Rhodesian Special Air Service in 1961. It retained the name "C Squadron (Rhodesian) Special Air Service" within the Rhodesian Security Forces until 1978, when it became 1 (Rhodesian) Special Air Service Regiment. Non-Commonwealth countries have also formed units based on the SAS. The Belgian Army's Special Forces Group, which wears the same capbadge as the British SAS, traces its ancestry partly from the 5th Special Air Service of the Second World War. The French 1st Marine Infantry Parachute Regiment (1er RPIMa) can trace its origins to the Second World War 3rd and 4th SAS, adopting its "who dares wins" motto. The American unit, 1st Special Forces Operational Detachment-Delta, was formed by Colonel Charles Alvin Beckwith, who served with 22 SAS as an exchange officer, and recognised the need for a similar type of unit in the United States Army.

== Treatment == As of 2018, there is no cure for GSD, and treatment is restricted to manage symptoms and associated problems. Thus, sodium bicarbonate is recommended to treat metabolic acidosis, and antioxidants, among them vitamins E and C, can reduce oxidative damage.

==== MeSH E05.478.605 – immunoprecipitation ==== MeSH E05.478.605.160 – chromatin immunoprecipitation MeSH E05.478.605.492 – precipitin tests MeSH E05.478.605.492.300 – flocculation tests MeSH E05.478.605.492.350 – immunodiffusion MeSH E05.478.605.492.350.350 – immunoelectrophoresis MeSH E05.478.605.492.350.350.150 – counterimmunoelectrophoresis MeSH E05.478.605.492.350.350.350 – immunoelectrophoresis, two-dimensional MeSH E05.478.605.825 – radioimmunoprecipitation assay

The mild acidic and chemoselective post Ugi activation of 5 involving simultaneous indolamide formation and tert-butoxycarbonyl (Boc) removal gives the active amide 6 which allows cyclization to 7 without affecting other peptidic or even ester moieties and with stereochemical retention of the chiral centers.

Sources: en.wikipedia.org

Background from the literature

== Commercial products == Several legal commercial products loosely based on the concept of "purple drank" are marketed in the United States. In June 2008, Innovative Beverage Group, a Houston, Texas-based company, released a beverage called "Drank". The commercial product contains no codeine or promethazine, but claims to "Slow Your Roll" with a combination of herbal ingredients such as valerian root and rose hips as well as the hormone melatonin. Similar "anti-energy" or relaxation drinks on the commercial market use the names "Purple Stuff", "Sippin Syrup", and "Lean". These commercial products have been criticized for their potential to serve as gateways to the dangerous illegal concoction. The marketing push has been described as akin to the making of candy cigarettes.

Foods are dried to inhibit microbial development and quality decay. However, the extent of drying depends on product end-use. Cereals and oilseeds are dried after harvest to the moisture content that allows microbial stability during storage. Vegetables are blanched before drying to avoid rapid darkening, and drying is not only carried out to inhibit microbial growth, but also to avoid browning during storage. Concerning dried fruits, the reduction of moisture acts in combination with its acid and sugar contents to provide protection against microbial growth. Products such as milk powder must be dried to very low moisture contents in order to ensure flowability and avoid caking. This moisture is lower than that required to ensure inhibition to microbial development. Other products as crackers are dried beyond the microbial growth threshold to confer a crispy texture, which is liked by consumers.

=== Web services in bioinformatics === SOAP- and REST-based interfaces have been developed to allow client computers to use algorithms, data and computing resources from servers in other parts of the world. The main advantage are that end users do not have to deal with software and database maintenance overheads. Basic bioinformatics services are classified by the EBI into three categories: SSS (Sequence Search Services), MSA (Multiple Sequence Alignment), and BSA (Biological Sequence Analysis). The availability of these service-oriented bioinformatics resources demonstrate the applicability of web-based bioinformatics solutions, and range from a collection of standalone tools with a common data format under a single web-based interface, to integrative, distributed and extensible bioinformatics workflow management systems.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.

Network